Lucid Diagnostics (LUCD) Share-based Compensation (2020 - 2026)
Lucid Diagnostics (LUCD) posted Share-based Compensation of $30000.0 for Q1 2026, down 97.42% on a QoQ basis from $1.2 million in Q4 2025, and down 97.09% year-over-year from $1.0 million in Q1 2025.
Lucid Diagnostics (LUCD) Share-based Compensation (2020 - 2026) Analysis & Trends
Lucid Diagnostics' Share-based Compensation history runs 7 years deep, the most recent figure standing at $30000.0 for Q1 2026.
- Quarterly Share-based Compensation fell 97.09% year-over-year to $30000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30000.0 (down 99.4% YoY) and the FY2025 annual result came in at $4.5 million, down 0.95% from the prior year.
- Share-based Compensation was $30000.0 for Q1 2026 at Lucid Diagnostics, down from $1.2 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.8 million in Q2 2022 and bottomed at $30000.0 in Q1 2026.
- A 5-year average of $1.8 million and a median of $1.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 376.4% — and 2026, when it sank 97.09%.
- Lucid Diagnostics' Share-based Compensation stood at $3.5 million in 2022, then plunged by 72.39% to $963000.0 in 2023, then soared by 55.76% to $1.5 million in 2024, then dropped by 22.33% to $1.2 million in 2025, then tumbled by 97.42% to $30000.0 in 2026.
- Business Quant data shows LUCD's Share-based Compensation at $30000.0 in Q1 2026, $1.2 million in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 317.00 Mn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 139.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 95.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 83.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 45.40 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 35.80 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 35.12 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 35.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Lucid Diagnostics | 133.09 Mn | 105.22 Mn | -325,000.00 | 30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 1.17 Mn |
| Dec 31, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Sep 30, 2025 | 1.15 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Mar 31, 2025 | 1.03 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Dec 31, 2024 | 1.50 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Sep 30, 2024 | 1.23 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.20 Mn |
| Mar 31, 2024 | 743,000.00 |
| Mar 31, 2024 | 743,000.00 |
| Dec 31, 2023 | 963,000.00 |
| Dec 31, 2023 | 963,000.00 |